tetano
Editor, Senior Moderator
Nat Commun
. 2021 Oct 5;12(1):5819.
doi: 10.1038/s41467-021-26113-1.
Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity
Hagit Achdout[SUP] #[/SUP][SUP] 1 [/SUP], Einat B Vitner[SUP] #[/SUP][SUP] 1 [/SUP], Boaz Politi[SUP] #[/SUP][SUP] 1 [/SUP], Sharon Melamed[SUP] #[/SUP][SUP] 1 [/SUP], Yfat Yahalom-Ronen[SUP] 1 [/SUP], Hadas Tamir[SUP] 1 [/SUP], Noam Erez[SUP] 1 [/SUP], Roy Avraham[SUP] 1 [/SUP], Shay Weiss[SUP] 1 [/SUP], Lilach Cherry[SUP] 1 [/SUP], Erez Bar-Haim[SUP] 2 [/SUP], Efi Makdasi[SUP] 1 [/SUP], David Gur[SUP] 2 [/SUP], Moshe Aftalion[SUP] 2 [/SUP], Theodor Chitlaru[SUP] 2 [/SUP], Yaron Vagima[SUP] 2 [/SUP], Nir Paran[SUP] 1 [/SUP], Tomer Israely[SUP] 3 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic. The continued spread of SARS-CoV-2 increases the probability of influenza/SARS-CoV-2 coinfection, which may result in severe disease. In this study, we examine the disease outcome of influenza A virus (IAV) and SARS-CoV-2 coinfection in K18-hACE2 mice. Our data indicate enhance susceptibility of IAV-infected mice to developing severe disease upon coinfection with SARS-CoV-2 two days later. In contrast to nonfatal influenza and lower mortality rates due to SARS-CoV-2 alone, this coinfection results in severe morbidity and nearly complete mortality. Coinfection is associated with elevated influenza viral loads in respiratory organs. Remarkably, prior immunity to influenza, but not to SARS-CoV-2, prevents severe disease and mortality. This protection is antibody-dependent. These data experimentally support the necessity of seasonal influenza vaccination for reducing the risk of severe influenza/COVID-19 comorbidity during the COVID-19 pandemic.
. 2021 Oct 5;12(1):5819.
doi: 10.1038/s41467-021-26113-1.
Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity
Hagit Achdout[SUP] #[/SUP][SUP] 1 [/SUP], Einat B Vitner[SUP] #[/SUP][SUP] 1 [/SUP], Boaz Politi[SUP] #[/SUP][SUP] 1 [/SUP], Sharon Melamed[SUP] #[/SUP][SUP] 1 [/SUP], Yfat Yahalom-Ronen[SUP] 1 [/SUP], Hadas Tamir[SUP] 1 [/SUP], Noam Erez[SUP] 1 [/SUP], Roy Avraham[SUP] 1 [/SUP], Shay Weiss[SUP] 1 [/SUP], Lilach Cherry[SUP] 1 [/SUP], Erez Bar-Haim[SUP] 2 [/SUP], Efi Makdasi[SUP] 1 [/SUP], David Gur[SUP] 2 [/SUP], Moshe Aftalion[SUP] 2 [/SUP], Theodor Chitlaru[SUP] 2 [/SUP], Yaron Vagima[SUP] 2 [/SUP], Nir Paran[SUP] 1 [/SUP], Tomer Israely[SUP] 3 [/SUP]
Affiliations
- PMID: 34611155
- DOI: 10.1038/s41467-021-26113-1
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic. The continued spread of SARS-CoV-2 increases the probability of influenza/SARS-CoV-2 coinfection, which may result in severe disease. In this study, we examine the disease outcome of influenza A virus (IAV) and SARS-CoV-2 coinfection in K18-hACE2 mice. Our data indicate enhance susceptibility of IAV-infected mice to developing severe disease upon coinfection with SARS-CoV-2 two days later. In contrast to nonfatal influenza and lower mortality rates due to SARS-CoV-2 alone, this coinfection results in severe morbidity and nearly complete mortality. Coinfection is associated with elevated influenza viral loads in respiratory organs. Remarkably, prior immunity to influenza, but not to SARS-CoV-2, prevents severe disease and mortality. This protection is antibody-dependent. These data experimentally support the necessity of seasonal influenza vaccination for reducing the risk of severe influenza/COVID-19 comorbidity during the COVID-19 pandemic.